First-line treatment with Relatlima + nivolumab demonstrated significant PFS benefit in patients with advanced melanoma

Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma. In this MEDtalk Evan J Lipson presents a human IgG4 LAG-3-blocking antibody in combination with nivolumab form the RELATIVITY-047 study.